CS MEDICA A/S: Publication of Annual Report 2022/2023

CS MEDICA releases its Annual Report 2022/2023 today. Highlights will be presented at a live-streamed conference call on Wednesday the 21 February at 10 AM CET.

CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby publishes its Annual Report 2022/2023 for the period October 2022 – September 2023, including the auditor’s report. The report is available as an attached document to this press release and on the Company’s website (www.cs-medica.com).

Highlights on the Year’s Performance, Challenges and Opportunities Ahead will be presented at a live-streamed conference call on Wednesday, 21 February at 10 AM CET. To register please use the following link: stokk.io/app/event/126/annual-report-20222023-presentation/ 

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and operating within the pharmaceutical industry. The company combines science and nature with the purpose of creating over-the-counter treatments to fight autoimmune and stress-related diseases, built upon our knowledge of the endocannabinoid system, patients' needs, and our experience in the pharmaceutical industry. We do so by pioneering scientific breakthroughs, expanding access to our treatments, understanding patients globally, and working to prevent the pain caused by the diseases we treat.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

Tags: